ATE216883T1 - Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker - Google Patents
Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blockerInfo
- Publication number
- ATE216883T1 ATE216883T1 AT97905107T AT97905107T ATE216883T1 AT E216883 T1 ATE216883 T1 AT E216883T1 AT 97905107 T AT97905107 T AT 97905107T AT 97905107 T AT97905107 T AT 97905107T AT E216883 T1 ATE216883 T1 AT E216883T1
- Authority
- AT
- Austria
- Prior art keywords
- nmda receptor
- receptor subtype
- hydrogen
- dihydro
- phenyl
- Prior art date
Links
- -1 4-PHENYL-3,6-DIHYDRO-2H-PYRIDYL Chemical class 0.000 title abstract 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96103636 | 1996-03-08 | ||
| PCT/EP1997/000951 WO1997032581A1 (en) | 1996-03-08 | 1997-02-27 | Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE216883T1 true ATE216883T1 (de) | 2002-05-15 |
Family
ID=8222541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97905107T ATE216883T1 (de) | 1996-03-08 | 1997-02-27 | Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5962472A (de) |
| EP (1) | EP0885004B1 (de) |
| JP (1) | JP3248917B2 (de) |
| KR (1) | KR100352358B1 (de) |
| CN (1) | CN1131031C (de) |
| AT (1) | ATE216883T1 (de) |
| AU (1) | AU717140B2 (de) |
| BR (1) | BR9708171A (de) |
| CA (1) | CA2248134A1 (de) |
| DE (1) | DE69712325T2 (de) |
| DK (1) | DK0885004T3 (de) |
| ES (1) | ES2174220T3 (de) |
| PT (1) | PT885004E (de) |
| TR (1) | TR199801774T2 (de) |
| WO (1) | WO1997032581A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1674087A1 (de) | 2000-10-02 | 2006-06-28 | Pfizer Products Inc. | Prophylaktische Verwendung von N-Methyl-D-Aspartat Rezeptor (NMDA) Antagonisten |
| JP2005506292A (ja) * | 2001-03-08 | 2005-03-03 | エモリー ユニバーシティ | ｐＨに依存するＮＭＤＡレセプターアンタゴニスト |
| US6951875B2 (en) | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| EP1689721B1 (de) * | 2003-11-26 | 2010-07-14 | Pfizer Products Inc. | Aminopyrazolderivate als gsk-3-inhibitoren |
| CN103497114A (zh) | 2007-06-29 | 2014-01-08 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
| NZ588698A (en) * | 2008-03-27 | 2012-06-29 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH507239A (de) * | 1968-12-24 | 1971-05-15 | Hoffmann La Roche | Verfahren zur Herstellung von aromatischen Äthern |
| CH558354A (de) * | 1970-06-17 | 1975-01-31 | Hoffmann La Roche | Verfahren zur herstellung von aromatischen aethern. |
| CH547802A (de) * | 1970-06-19 | 1974-04-11 | Hoffmann La Roche | Verfahren zur herstellung von tetrahydropyridinderivaten. |
| US3879405A (en) * | 1970-06-19 | 1975-04-22 | Hoffmann La Roche | Tetrahydropyridine derivatives |
| US5149817A (en) * | 1990-03-05 | 1992-09-22 | Shionogi & Co., Ltd. | Teirahydropyridine derivatives |
| DE4325855A1 (de) | 1993-08-02 | 1995-02-09 | Boehringer Ingelheim Kg | Neue Benzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4325885A1 (de) * | 1993-08-02 | 1995-02-09 | Basf Ag | Elektrolumineszierende Anordnung |
| DE4410822A1 (de) * | 1994-03-24 | 1995-09-28 | Schering Ag | Neue Piperidin-Derivate |
| US5698565A (en) | 1995-06-09 | 1997-12-16 | Hoffmann-La Roche Inc. | Use of phenoxy-pyridine derivatives |
-
1997
- 1997-02-27 ES ES97905107T patent/ES2174220T3/es not_active Expired - Lifetime
- 1997-02-27 CN CN97192889A patent/CN1131031C/zh not_active Expired - Fee Related
- 1997-02-27 DE DE69712325T patent/DE69712325T2/de not_active Expired - Fee Related
- 1997-02-27 WO PCT/EP1997/000951 patent/WO1997032581A1/en not_active Ceased
- 1997-02-27 DK DK97905107T patent/DK0885004T3/da active
- 1997-02-27 TR TR1998/01774T patent/TR199801774T2/xx unknown
- 1997-02-27 KR KR10-1998-0706936A patent/KR100352358B1/ko not_active Expired - Fee Related
- 1997-02-27 EP EP97905107A patent/EP0885004B1/de not_active Expired - Lifetime
- 1997-02-27 CA CA002248134A patent/CA2248134A1/en not_active Abandoned
- 1997-02-27 AT AT97905107T patent/ATE216883T1/de not_active IP Right Cessation
- 1997-02-27 JP JP53141697A patent/JP3248917B2/ja not_active Expired - Fee Related
- 1997-02-27 AU AU18782/97A patent/AU717140B2/en not_active Ceased
- 1997-02-27 BR BR9708171A patent/BR9708171A/pt not_active Application Discontinuation
- 1997-02-27 PT PT97905107T patent/PT885004E/pt unknown
- 1997-03-07 US US08/813,523 patent/US5962472A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1213304A (zh) | 1999-04-07 |
| EP0885004A1 (de) | 1998-12-23 |
| ES2174220T3 (es) | 2002-11-01 |
| DK0885004T3 (da) | 2002-08-19 |
| KR100352358B1 (ko) | 2003-03-10 |
| AU1878297A (en) | 1997-09-22 |
| AU717140B2 (en) | 2000-03-16 |
| JP2000507542A (ja) | 2000-06-20 |
| EP0885004B1 (de) | 2002-05-02 |
| TR199801774T2 (xx) | 1998-12-21 |
| CA2248134A1 (en) | 1997-09-12 |
| DE69712325D1 (de) | 2002-06-06 |
| CN1131031C (zh) | 2003-12-17 |
| KR19990087505A (ko) | 1999-12-27 |
| JP3248917B2 (ja) | 2002-01-21 |
| WO1997032581A1 (en) | 1997-09-12 |
| BR9708171A (pt) | 1999-07-27 |
| DE69712325T2 (de) | 2002-11-28 |
| US5962472A (en) | 1999-10-05 |
| PT885004E (pt) | 2002-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200700232A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| DK0687268T3 (da) | Spiroazacykliske derivater som substans P-antagonister | |
| ATE139233T1 (de) | Annelierte thiophen-derivate, ihre herstellung und verwendung | |
| HUP0001192A2 (hu) | Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására | |
| DK0533280T3 (da) | Ny medicinsk anvendelse af tachykininantagonister | |
| NO954694L (no) | Doseringsform for antidepressiva | |
| DE69523169D1 (de) | Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung | |
| DE69616480D1 (de) | Piperidinderivate als neurokininantagonisten | |
| ES2176204T3 (es) | Antidepresivos que contienen un derivado de xantina. | |
| WO1993014084A3 (en) | Piperidine derivatives | |
| MY114425A (en) | Quinazoline derivatives | |
| JO2321B1 (en) | 4-phenyl-pyridine derivatives | |
| WO1999024022A3 (en) | Isoquinoline derivatives for treating disorders associated with 5ht7 receptors | |
| DK0779284T3 (da) | Hidtil ukendte 2-naphtanamidderivater og terapeutiske anvendelser heraf som agonister af D3-receptorer | |
| NO20001514L (no) | Vitronectin-reseptor-antagonist | |
| ATE216883T1 (de) | Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker | |
| ES2073258T3 (es) | Nuevos derivados de la urea, su preparacion y su aplicacion en terapeutica. | |
| DE69412073D1 (de) | Xanthinderivate als adenosin-a1 rezeptor antagonisten | |
| NO973241L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av hyperlipoproteinemi, hypertriglyceridemi, hyperlipidemi eller hyperkolesterolemi, eller arteriosklerose, eller for antikoagulativ b | |
| NO20023041L (no) | Fremgangsmåte for fremstilling av pyrazolopyridazinderivater | |
| ES2162078T3 (es) | Compuestos terapeuticos. | |
| DE59904415D1 (de) | Verwendung von Moxonidin als Thermogenese stimulierend wirksames Arzneimittel | |
| YU61096A (sh) | Novi intermedijari, njihova primena u sintezi n,n'-premoštenih bisindolilmaleimida i farmaceutske formulacije | |
| NO992316L (no) | Benzensulfonamidderivater og legemidler inneholdende disse | |
| DK1082116T3 (da) | Anvendelse af 4-piperidinmethanolderivater til behandling af neurologiske sygdomme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |